RT Journal Article
SR Electronic
T1 Salvage treatment in patients with recurrent or resistant malignant pleura mesothelioma. A retrospective study from tertiary oncology department
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA5074
DO 10.1183/13993003.congress-2016.PA5074
VO 48
IS suppl 60
A1 Andriani Charpidou
A1 George Tsironis
A1 Sofia Tsagouli
A1 Aris Nikolaou
A1 Antonis Bassias
A1 Ilias Kainis
A1 Marios Zontanos
A1 Sotiris Tsimpoukis
A1 Kosts Syrigos
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA5074.abstract
AB Introduction: The platinum- pemetrexed doublet is the golden standard for the first line chemotherapy in Malignant Mesothelioma (MM) . As a result of very often relapse, second line chemotherapy choice is crucial for patients survival.Methods: A number of 98 patients with MM, treated in a tertiary Oncology Unit were reviewed and analyzed.Results: 50 patients (86%M/ 14%F, median age 66 years, 74% PS 0-1, 98% pleural MM, 82,93% with epithelial histology) received second line chemotherapy, resulting in 6,25% PR, 25% SD, 31,25% DC and 56,25% PD Median PFS of 3,02 months (95%CI 2,72- 4,89), 18,98 months mOS (95%CI 16,16- 23,09) and 6,93 months median survival from the start of second line (95%CI 5,02- 10,38).48% of patients (24) received a taxane– gemcitabine with 0% PR, 21,74% SD, 21,74% DC, 69,57% PD, 2,98m mPFS (95%CI 2,59-3,38), 15,34m mOS (95%CI 11,43- 20,50) and 5,88m m2LS (95%CI 2,85- 8,41).18% (9) had docetaxel monotherapy. None of them had achieved PR, and 55,56% progressed resulting in 3,02m mPFS (95%CI 0,78- 9,39), 22,96m mOS (95%CI 6,99- ) and 5,48m m2LS (95%CI 0,88- ).Finally 8 patients (16%) received the third most common second line option,with pemetrexed doublet (6/ 12%) or pemetrexed monotherapy (2/ 4%). The 14,29% of them achieved PR, 57,14% SD, 71,43% DC and 28,57%PD resulting in 7,35m mPFS (95%CI 2,06- 32,52), 29,20m mOS (95%CI 18,98- ) and 11,13m m2LS (95%CI 6,66- ).Conclusions: Re-challenge therapy with pemetrexed is the most effective solution. Limitation of the study is the heterogeneity ot treatment groups.